Hiroya Kobayashi

Asahikawa, 0788510, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications

Synergistic activation of STING and CD40 in the tumor microenvironment enhances CD8+ T-cell-dependent antitumor immunity.

Synergistic activation of STING and CD40 in the tumor microenvironment enhances CD8+ T-cell-dependent antitumor immunity.

Journal: Biochemical and biophysical research communications
Published: November 12, 2025

ROR1 as an Immunotherapeutic Target for Inducing Antitumor Helper T Cell Responses Against Head and Neck Squamous Cell Carcinoma.

ROR1 as an Immunotherapeutic Target for Inducing Antitumor Helper T Cell Responses Against Head and Neck Squamous Cell Carcinoma.

Journal: Cancers
Published: June 09, 2025

Dipeptidyl Peptidase 4 Restoration Facilitates Antitumor Immunity in KRAS-LKB1-Mutant Lung Cancer.

Dipeptidyl Peptidase 4 Restoration Facilitates Antitumor Immunity in KRAS-LKB1-Mutant Lung Cancer.

Journal: Cancer research communications
Published: April 07, 2025

Tumor-promoting function of paternally expressed gene 10 and its immunogenicity in inducing anti-tumor helper T cells in head and neck squamous cell carcinoma.

Tumor-promoting function of paternally expressed gene 10 and its immunogenicity in inducing anti-tumor helper T cells in head and neck squamous cell carcinoma.

Journal: Cancer immunology, immunotherapy : CII
Published: March 18, 2025

Differences in PD-L1, PD-L2, and EGFR Expression Between Naive and Recurrent Tumors in Patients With Head and Neck Squamous Cell Carcinoma: A Retrospective Study.

Differences in PD-L1, PD-L2, and EGFR Expression Between Naive and Recurrent Tumors in Patients With Head and Neck Squamous Cell Carcinoma: A Retrospective Study.

Journal: Head & neck
Published: February 03, 2025

Hypoxia-Targeted Immunotherapy with PD-1 Blockade in Head and Neck Cancer.

Hypoxia-Targeted Immunotherapy with PD-1 Blockade in Head and Neck Cancer.

Journal: Cancers
Published: July 30, 2024

NF9 peptide specific cytotoxic T lymphocyte clone cross react to Y453F mutation of SARS-CoV-2 virus spike protein.

NF9 peptide specific cytotoxic T lymphocyte clone cross react to Y453F mutation of SARS-CoV-2 virus spike protein.

Journal: Immunological medicine
Published: January 18, 2024

Immunotherapy targeting tumor-associated antigen in a mouse model of head and neck cancer.

Immunotherapy targeting tumor-associated antigen in a mouse model of head and neck cancer.

Journal: Head & neck
Published: October 19, 2023

Soluble CD27 as a predictive biomarker for intra-tumoral CD70/CD27 interaction in nasopharyngeal carcinoma.

Soluble CD27 as a predictive biomarker for intra-tumoral CD70/CD27 interaction in nasopharyngeal carcinoma.

Journal: Cancer science
Published: September 01, 2023

Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer.

Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer.

Journal: Cancer immunology, immunotherapy : CII
Published: February 06, 2023

SARS-CoV-2 spike protein-derived immunogenic peptides that are promiscuously presented by several HLA-class II molecules and their potential for inducing acquired immunity.

SARS-CoV-2 spike protein-derived immunogenic peptides that are promiscuously presented by several HLA-class II molecules and their potential for inducing acquired immunity.

Journal: Heliyon
Published: December 10, 2022

Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy.

Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy.

Journal: Cancer immunology, immunotherapy : CII
Published: August 17, 2022
Showing 1-12 of 55

Last Updated: 09/26/2026